Product Description
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
Mechanisms of Action: S1P1 Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belarus, Bulgaria, Czech Republic, Georgia, Germany, Hungary, Italy, Moldova, Poland, Russia, Serbia, Taiwan, Ukraine, United States, Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AMUC-2023 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2024-09-01 |
24% |
| 2020-005232-30 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2024-03-02 |
|
| jRCT2031210352 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2023-10-31 |